Indications and Dosing

  • CELEBREX should be used at the lowest effective dose for the shortest duration consistent with treatment goals for the individual patient
  • CELEBREX can be administered without regard to timing of meals
  • CELEBREX is available in 4 strengths: 50 mg, 100 mg, 200 mg, and 400 mg capsules
 
  • Osteoarthritis (OA)

    CELEBREX is indicated for the management of the signs and symptoms of OA.

    200 mg once daily or 100 mg twice per day
  • Rheumatoid Arthritis (RA)

    CELEBREX is indicated for the management of the signs and symptoms of RA.

    100 mg to 200 mg twice per day
  • Acute Pain in Adults

    CELEBREX is indicated for the management of acute pain in adults.

    Day 1: 400-mg initial dose + 200 mg if needed
    Days >1: 200 mg twice per day as needed
  • Ankylosing Spondylitis

    CELEBREX is indicated for the management of signs and symptoms of ankylosing spondylitis.

    Starting dose 200 mg in single (once per day) or divided (twice per day) doses
    If no effect
    after 6 weeks
    A trial of 400 mg daily may be worthwhile
    If no effect after 6 weeks on 400 mg daily A response is not likely and an alternate treatment should be considered
  • Primary Dysmenorrhea

    CELEBREX is indicated for the management of primary dysmenorrhea.

    Day 1: 400-mg initial dose + 200 mg if needed
    Days >1: 200 mg twice per day as needed
  • Juvenile Rheumatoid Arthritis (JRA)

    CELEBREX is indicated for the management of the signs and symptoms of JRA in pediatric patients ≥2 years.

    Patients 10 kg to 25 kg (22 lb to 55 lb): 50 mg twice per day
    Patients >25 kg (>55 lb): 100 mg twice per day

    NSAIDs, including CELEBREX, should be used with caution in pediatric patients with systemic onset JRA, due to the risk of disseminated intravascular coagulation.

  • Special Populations

    Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B).

    Initiate treatment with half of the lowest recommended dose in adult patients who are known or suspected to be poor CYP2C9 metabolizers

    Consider using alternative treatments in JRA patients who are known or suspected to be poor CYP2C9 metabolizers

*Eligibility required. Terms and conditions apply. Full terms and conditions can be found at CELEBREX.com/savings-terms. This Savings Offer will be accepted only at participating pharmacies. This Savings Offer is not health insurance. No membership fees. Maximum savings of $1,750 per offer. This Savings Offer is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs. This Savings Offer is not valid for prescriptions that are eligible to be reimbursed in whole by private insurance plans or other health or pharmacy benefit programs. Pfizer reserves the right to revoke, rescind, or amend this offer without notice. For help with the CELEBREX Savings Offer, call 1-855-612-1956, visit CELEBREX.com, or write: Pfizer Inc., 235 E 42nd Street, New York, NY 10017.

Back to top